Unmet Needs and Future Treatments of Idiopathic Pulmonary Fibrosis

Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis.

Dr Nathan highlights the role of PDE4B inhibitors in IPF management.

Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.

Dr Nathan discusses the trajectory of IPF management.

Dr Nathan provides his final thoughts regarding IPF management.

Justin Oldham, MD, MS, discusses the current standard of car in treating idiopathic pulmonary fibrosis and the role of non-pharmacologic therapies.

An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.

Decision-making factors surrounding optimal IPF treatment selection are evaluated by Justin Oldham, MD, MS.

The panel explores how IPF affects patient productivity and its contribution to the disease's overall economic burden.

Critical voids in the management of idiopathic pulmonary fibrosis are discussed by Justin Oldham, MD, MS.